Literature DB >> 16946457

Update of the drug resistance mutations in HIV-1: Fall 2006.

Victoria A Johnson1, Francoise Brun-Vezinet, Bonaventura Clotet, Daniel R Kuritzkes, Deenan Pillay, Jonathan M Schapiro, Douglas D Richman.   

Abstract

The International AIDS Society-USA (IAS-USA) Drug Resistance Mutations Group is marking 6 years as an independent volunteer panel of experts focused on identifying key HIV-1 drug resistance mutations. The goal of the effort is to quickly deliver accurate and unbiased information on these mutations to HIV clinical practitioners. This version of the IAS-USA Drug Resistance Mutations Figures replaces the version published in this journal in October/November 2005. The IAS-USA Drug Resistance Mutations Figures are designed for use in identifying mutations associated with viral resistance to antiretroviral drugs and in making therapeutic decisions. Care should be taken when using this list of mutations for surveillance or epidemiologic studies of transmission of drug-resistant virus. A number of amino acid substitutions, particularly minor mutations, represent polymorphisms that in isolation may not reflect prior drug selective pressure or reduced drug susceptibility.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16946457

Source DB:  PubMed          Journal:  Top HIV Med        ISSN: 1542-8826


  67 in total

1.  Synthesis and Anti-HIV-1 Activity of a Novel Series of Aminoimidazole Analogs.

Authors:  Swastika Ganguly; Sankaran Murugesan; Naru Prasanthi; Onur Alptürk; Brian Herman; Nicolas Sluis-Cremer
Journal:  Lett Drug Des Discov       Date:  2010-06-01       Impact factor: 1.150

2.  Feasibility of detecting human immunodeficiency virus type 1 drug resistance in DNA extracted from whole blood or dried blood spots.

Authors:  Kim Steegen; Stanley Luchters; Els Demecheleer; Kenny Dauwe; Kishor Mandaliya; Walter Jaoko; Jean Plum; Marleen Temmerman; Chris Verhofstede
Journal:  J Clin Microbiol       Date:  2007-08-01       Impact factor: 5.948

3.  Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate.

Authors:  Johan Lennerstrand; Chung K Chu; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2007-04-02       Impact factor: 5.191

4.  Dual selection pressure by drugs and HLA class I-restricted immune responses on human immunodeficiency virus type 1 protease.

Authors:  Sandra M Mueller; Birgit Schaetz; Kathrin Eismann; Silke Bergmann; Michael Bauerle; Matthias Schmitt-Haendle; Hauke Walter; Barbara Schmidt; Klaus Korn; Heinrich Sticht; Bernd Spriewald; Ellen G Harrer; Thomas Harrer
Journal:  J Virol       Date:  2007-01-03       Impact factor: 5.103

5.  Predictive genotypic algorithm for virologic response to lopinavir-ritonavir in protease inhibitor-experienced patients.

Authors:  Martin S King; Richard Rode; Isabelle Cohen-Codar; Vincent Calvez; Anne-Geneviève Marcelin; George J Hanna; Dale J Kempf
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

6.  In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.

Authors:  Sherie Masse; Xiaozhi Lu; Tatyana Dekhtyar; Liangjun Lu; Gennadiy Koev; Feng Gao; Hongmei Mo; Dale Kempf; Barry Bernstein; George J Hanna; Akhteruzzaman Molla
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

7.  Prevalence of drug-resistant HIV-1 in rural areas of Hubei province in the People's Republic of China.

Authors:  Minqi Luo; Huan Liu; Ke Zhuang; Li Liu; Bo Su; Rongrong Yang; Po Tien; Linqi Zhang; Xien Gui; Zhiwei Chen
Journal:  J Acquir Immune Defic Syndr       Date:  2009-01-01       Impact factor: 3.731

8.  Survival, plasma HIV-1 RNA concentrations and drug resistance in HIV-1-infected Haitian adolescents and young adults on antiretrovirals.

Authors:  Macarthur Charles; Francine Noel; Paul Leger; Patrice Severe; Cynthia Riviere; Carole Anne Beauharnais; Erica Miller; John Rutledge; Heejung Bang; Wesley Shealey; Richard T D'Aquila; Roy M Gulick; Warren D Johnson; Peter F Wright; Jean William Pape; Daniel W Fitzgerald
Journal:  Bull World Health Organ       Date:  2008-12       Impact factor: 9.408

9.  Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.

Authors:  Anne-Geneviève Marcelin; Philippe Flandre; Jean-Michel Molina; Christine Katlama; Patrick Yeni; Francois Raffi; Zeina Antoun; Mounir Ait-Khaled; Vincent Calvez
Journal:  Antimicrob Agents Chemother       Date:  2008-10-13       Impact factor: 5.191

10.  A poke in the eye: inhibiting HIV-1 protease through its flap-recognition pocket.

Authors:  Kelly L Damm; Peter M U Ung; Jerome J Quintero; Jason E Gestwicki; Heather A Carlson
Journal:  Biopolymers       Date:  2008-08       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.